Corella Resources Ltd (cr9) Logo

Corella Resources Ltd (CR9)

___:___ · Basic Materials
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

CR9 Chart

Snapshot

CR9's Principal Activity is the reviewing potential acquisition opportunities.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) +1446.56%

Size

Market Capitalisation
ASX Rank 1,902 of 2,316
Sector Rank 591 of 802

Key Fundamentals

Shares Issued
Sector Basic Materials
Similar Companies RFR / CY5 / PSL
EPS -$0.011
DPS $0.00
NTA per share $0.00

Broker Consensus

CR9 is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Corella Resources Ltd (CR9, formerly Sinetech Limited) is an Australian exploration company, focuses on the exploration of the following wholly owned, high-grade, low impurity kaolin and silica projects located in the Yilgarn Craton region of Western Australia: Tampu Kaolin Project, Wiltshire Kaolin Project, Kalannie Kaolin Project and Bonnie Rock Silica Project.

Incorporation Details

Incorporated Incorporated on 14 June 2007 in Western Australia.

Corporate Details

Head Office Subiaco WA 6008
Website www.corellaresources.com.au
Registry Automic Group
Auditor UHY Haines Norton
Date Listed 15 Jan 2008

Upcoming Calendar (Forecasted)

Date Event
25/02/2022 Report (Interim)
18/07/2022 Report (Quarterly)
29/09/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Anthony (Tony) Stephen Cormack Non-Executive Director Apr 2021 Director Bio icon

Mr Anthony (Tony) Stephen Cormack

Non-Executive Director

--

Mr Philip Re Non-Executive Director Apr 2021 Director Bio icon

Mr Philip Re

Non-Executive Director

--

Mr Peter Woods Non-Executive Director Apr 2021 Director Bio icon

Mr Peter Woods

Non-Executive Director

--

Mr Daniel Coletta Joint Company Secretary Dec 2020 Director Bio icon

Mr Daniel Coletta

Joint Company Secretary

Mr Coletta has experience in accounting and compliance.

Mr Derek Hall Company Secretary Dec 2019 Director Bio icon

Mr Derek Hall

Company Secretary

Mr Hall is a finance and compliance specialist in the listed space. Mr Hall has commercial experience identifying key business drivers and bringing cost control and process improvement into sharp focus. Mr Hall has been involved as a Chief Financial Officer and Company Secretary for a number of publicly listed and unlisted companies involving transactions in technology, mining, oil and gas and construction.

Dr Paul Bello Joint Company Secretary Oct 2008
Mr Giorgio Reggiani Company Secretary Feb 2008
Mr Harry Karelis Non-Executive Director N/A Director Bio icon

Mr Harry Karelis

Non-Executive Director

--

Mr Leslie Harold Webb Non-Executive Director N/A Director Bio icon

Mr Leslie Harold Webb

Non-Executive Director

Mr Webb was establishing ITV Consulting Pty Limited, a corporate advisory and investment consulting business. He is also a Non-executive Director of pharmaceutical company Generic Health Limited and health insurance company iSelect. He previously sat on the Board of the ASX listed Gradipore Ltd (now Life Therapeutics).

Mr David Dodd Chairman N/A Director Bio icon

Mr David Dodd

Chairman

Mr Dodd's experience includes management and corporate development experience in the life sciences industry. Prior to joining the Stem Cell Sciences, he was President, Chief Executive Officer and Director of NASDAQ quoted Serologicals Corporation until it was acquired by Millipore Corporation on 14 July 2006. From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals Inc. and as a member of the Management Board for the Pharmaceutical Sector for Solvay SA. He was also Chairman of the Board of Unimed Pharmaceuticals Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories. He was awarded the 2005 GBP Biomedical Industry Growth Award for his efforts in promoting Georgia's life sciences industry. In addition, he received the 2005 Oglethorpe Award from the Atlanta Chapter of the British American Business Group, in recognition of his ongoing leadership in fostering business relationships between the USA and the United Kingdom. David is also currently serving on the board of directors of Stheno Corporation, a private life sciences instrument company, as Non-executive Director; as Chairman of the Board of the American Foundation for Suicide Prevention; and, as Immediate Past-Chair, the Georgia Biomedical Partnership, and the biotechnology trade association in the State of Georgia. He was appointed President, CEO and Chairman of Bioreliance Corporation on 3 December 2007.

Dr Peter Mountford Non-Executive Director N/A Director Bio icon

Dr Peter Mountford

Non-Executive Director

Dr Mountford is currently a Director of all the companies within Stem Cell Sciences, as well as of the private company Secure Sciences Pty Ltd.

Dr Michael (Mike) Dexter Non-Executive Director N/A Director Bio icon

Dr Michael (Mike) Dexter

Non-Executive Director

Dr Dexter spent the five years prior to joining Stem Cell Sciences as Director (Chief Executive Officer) of The Wellcome Trust. During his time at The Wellcome Trust, he oversaw one of the biggest advances in biomedical research when it was announced that the human genome had been sequenced - giving scientists a detailed map of the body's make-up for the first time. Prior to joining The Wellcome Trust, he was Director of Research at the Paterson Institute for Cancer Research, Christie Hospital, NHS Trust, Manchester. He is a Fellow of the Royal Society (London), was appointed Professor of Experimental Oncology at the University of Manchester and is an honorary Fellow of the Royal College of Physicians and a founding fellow of the Academy of Medical Sciences. He is currently Chairman of the International Centre for Life, Newcastle, and the Cockcroft Institute for Accelerator Sciences in Daresbury, Cheshire. He was previously a Director of Catalyst Biomedica Ltd, the translational business arm of The Wellcome Trust. He has over 360 publications on his scientific work.

Dr Alastair James Riddell Chief Executive Officer N/A Director Bio icon

Dr Alastair James Riddell

Chief Executive Officer

Dr Riddell has more than 24 years experience in this industry. He has spent time at Board level building companies, raising money and negotiating corporate deals. From 2006 to 2007, he held the position of Non-executive Chairman at Surface Therapeutics prior to its sale to Serentis in September 2007. From 2005, he was Chief Executive Officer of Paradigm Therapeutics where he achieved a trade sale to Takeda Pharmaceutical Corporation in March 2007. Prior to Paradigm, he was Chief Executive Officer of Pharmagene for seven years, during which time he listed the company on the main market of the London Stock Exchange. He has also held senior positions with Celltech, Centocor and Amersham International in clinical development before moving to sales and marketing. He began his professional career as a medical doctor with six years, experience in a variety of hospital specialties and in general practice. He is an active Board member of the BIA, a position he has held from 2000 to 2006 and recently re-elected to serve for the 2008 term. In November 2007, he joined the Board of Sareum Holdings plc as Non-executive Director.

Paul Bello Joint Company Secretary N/A

Director Transactions

CR9 directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
20/04/21 Warren Barry Issued 3,627,753 $0.003 $10,883 Director remuneration
20/04/21 Warren Barry Issued 581,402 $0.02 $11,628 Director remuneration
20/04/21 Terence (Terry) Butler Issued 1,976,525 $0.02 $39,530 Director remuneration
20/04/21 Terence (Terry) Butler Issued 5,525,918 $0.003 $16,577 Director remuneration
20/04/21 Derek Hall Issued 2,674,086 $0.003 $8,022 Director remuneration
20/04/21 Derek Hall Issued 2,674,086 $0.02 $53,481 Director remuneration
01/04/21 Warren Barry Transfer 48,427,031 $0.003 $145,281 Off-market transfer
01/04/21 Warren Barry Transfer 48,427,031 $0.003 $145,281 Off-market transfer

Director Interests

The current holdings of CR9 directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Daniel Coletta 23/04/2021 0 N/A N/A N/A
Peter Woods 23/04/2021 N/A 22,000,000 4,500,000 N/A
Philip Re 23/04/2021 N/A 7,000,000 4,500,000 N/A
Anthony (Tony) Cormack 23/04/2021 13,909,091 N/A N/A N/A
Derek Hall 23/04/2021 0 2,674,086 2,674,086 N/A
Alastair Riddell 23/05/2008 N/A N/A 1,005,484 N/A
Peter Mountford 20/03/2008 N/A 3,368,633 N/A N/A
David Dodd 09/10/2006 65,420 N/A N/A N/A
Michael (Mike) Dexter N/A N/A N/A N/A N/A
Leslie Webb N/A N/A N/A N/A N/A
Harry Karelis N/A N/A N/A N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Aug 31, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Spruson Corporation Pty Ltd <Booyah Family A/C> 71,935,828 7.10%
Terence Butler & Rosemary Butler <Butler Super Fund A/C> 59,437,876 5.86%
BTR Holdings Pty Ltd <Mushy One A/C> 56,488,421 5.57%
Rimoyne Pty Ltd 50,000,000 4.93%
Barry Consulting Pty Ltd <Barry Family A/C> 48,427,031 4.78%
Ligurian Holdings Pty Ltd 47,500,229 4.69%
Marindo Nominees Pty Ltd 41,250,000 4.07%
Mingoola Pty Ltd 37,543,051 3.70%
On Time Taxis Pty Ltd 25,000,000 2.47%
Crossbay Pty Ltd 25,000,000 2.47%
Philip Re & Leah Re <Re Family Super Fund A/C> 25,000,000 2.47%
Blueseas Investments Pty Ltd <Asean Super Fund A/C> 22,533,182 2.22%
Luigi Baccini & & Loredana Baccini <Baccini Super Fund A/C> 20,000,000 1.97%
Chembank Pty Limited <Cabac Super Fund A/C> 20,000,000 1.97%
MSJ Capital Pty Limited <Msj Family A/C> 19,960,799 1.97%
Traditional Securities Group Pty Ltd <Lpr Family A/C> 16,000,229 1.58%
MSJ Capital Pty Limited <The Harrison S/F A/C> 15,414,746 1.52%
Tyson Kane Smith 15,000,000 1.48%
Mandevilla Pty Ltd 14,050,000 1.39%
Medidew Pty Ltd <The Medidew A/C> 12,879,317 1.27%
Warren Barry & Sonia Barry <Barry Family Superfund A/C> 12,500,000 1.23%
Capretti Investments Pty Ltd <Castello A/C> 11,786,696 1.16%
Ant (Act) Nominees Pty Limited <Butler Family A/C> 11,550,000 1.14%
Perizia Investments Pty Ltd 11,550,000 1.14%
Stephen Harrison 11,550,000 1.14%

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Spruson Corporation Pty Ltd 31/08/2020 71,935,828 7.10
Terence Butler 31/08/2020 59,437,876 5.86
BTR Holdings Pty Ltd 31/08/2020 56,488,421 5.57

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
27-04-21 Jason Peterson 22,000,000 -- 5.18

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
30-09-21 Jason Peterson 22,000,000 5.18 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
CR9 Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.